

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/511,537	First Named Inventor: Tiden
Filing Date: October 15, 2004	Attorney Docket No.: 100647-1P US
Examiner: Mark L. Berch	Group Art Unit : 1624
Customer No.: 22466	Confirmation No.: 4417
Title: Thioxanthine Derivatives as Myeloperoxidase Inhibitors	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir,

Pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56, Applicants submit herewith USPTO Form SB08a citing U.S. Patent No. 4,710,503, which was cited in an Office Action, issued January 31, 2008 by the Colombian Patent Office in relation to the Colombian counterpart of the above referenced U.S. application. Applicants herewith submit the Office Action issued by the Colombian Patent Office on January 31, 2008. Applicants kindly request the Examiner acknowledge receipt and consideration of the Colombian Office Action in the next Office Action issued by the Examiner.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), a copy of U.S Patent No. 4,710,503 is not submitted herewith.

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114 and within 3 months of receipt of a first citation of such reference in a foreign counterpart application.

It is respectfully requested the Examiner consider and make of record U.S. Patent No. 4,710,503 and the Office Action issued January 31, 2008 by the Colombian Patent Office.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100647-1P US.

Respectfully submitted,
/Jacqueline M. Cohen/

Name: Jacqueline M. Cohen
Dated: April 30, 2008
Reg. No.: 51,574
Phone No.: 302-885-4269
Global Intellectual Property, Patents,
AstraZeneca
1800 Concord Pike
Wilmington
DE-19850-5437